Genmab A/S (GMAB) Stock Forecast
Data as of Aug 7, 2026Healthcare · Current price $31.13 (+4.32%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
GMAB vs Sector & Market
| Metric | GMAB | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.42 |
| Analyst Count | 3 | 8 | 18 |
| Target Upside | +35.5% | +16316.1% | +17.2% |
| P/E Ratio | 4.20 | 3.40 | 35.26 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $1.11B | $1.14B | $1.17B | 2 |
| 2026-12-31 | $1.15B | $1.18B | $1.22B | 2 |
| 2027-03-31 | $1.04B | $1.07B | $1.10B | 2 |
| 2027-06-30 | $1.16B | $1.19B | $1.23B | 2 |
| 2027-09-30 | $1.22B | $1.26B | $1.29B | 2 |
| 2027-12-31 | $1.29B | $1.33B | $1.37B | 2 |
| 2028-03-31 | $1.17B | $1.21B | $1.24B | 1 |
| 2028-06-30 | $1.39B | $1.43B | $1.47B | 1 |
| 2028-09-30 | $1.52B | $1.56B | $1.61B | 1 |
| 2028-12-31 | $1.64B | $1.69B | $1.73B | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $0.35 | $0.36 | $0.37 | 1 |
| 2026-12-31 | $0.36 | $0.37 | $0.39 | 2 |
| 2027-03-31 | $0.27 | $0.28 | $0.29 | 1 |
| 2027-06-30 | $0.38 | $0.39 | $0.41 | 1 |
| 2027-09-30 | $0.43 | $0.45 | $0.47 | 1 |
| 2027-12-31 | $0.51 | $0.53 | $0.55 | 1 |
| 2028-03-31 | $0.45 | $0.47 | $0.49 | 1 |
| 2028-06-30 | $0.67 | $0.69 | $0.72 | 1 |
| 2028-09-30 | $0.77 | $0.80 | $0.82 | 1 |
| 2028-12-31 | $0.88 | $0.91 | $0.94 | 1 |
Frequently Asked Questions
What is the analyst consensus for GMAB?
The consensus among 3 analysts covering Genmab A/S (GMAB) is Buy with an average price target of $38.30.
What is the highest price target for GMAB?
The highest analyst price target for GMAB is $41.50.
What is the lowest price target for GMAB?
The lowest analyst price target for GMAB is $32.00.
How many analysts cover GMAB?
3 analysts have issued ratings for Genmab A/S in the past 12 months.
Is GMAB a buy or sell right now?
Based on 3 analyst ratings, GMAB has a consensus rating of Buy (2.00/5) with a +35.5% upside to the consensus target of $38.30.
What are the earnings estimates for GMAB?
Analysts estimate GMAB will report EPS of $0.36 for the period ending 2026-09-30, with revenue estimated at $1.14B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.